Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lemborexant - Eisai

Drug Profile

Lemborexant - Eisai

Alternative Names: DAYVIGO; DAYVIGOTM; E-2006; LEM - Eisai

Latest Information Update: 14 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Inc
  • Class Amides; Cyclopropanes; Fluorobenzenes; Pyridines; Pyrimidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Insomnia
  • Phase II Circadian rhythm sleep disorders
  • Phase I Chronic obstructive pulmonary disease; Sleep apnoea syndrome

Most Recent Events

  • 30 Nov 2022 Eisai initiates a phase II trial for Insomnia in South Korea (PO, Tablet) (NCT05594589)
  • 26 Oct 2022 Eisai plans a phase-II trial for Insomnia in November 2022 (PO, Tablet) (NCT05594589)
  • 02 Apr 2022 Efficacy data from a phase III SUNRISE trial in Insomnia presented at the 74th Annual Meeting of the American Academy of Neurology (AAN-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top